William Blair acted as the exclusive financial advisor to Metalmark Capital Partners (Metalmark) in connection with its growth investment in Morgenesis LLC, the point-of-care (POCare) subsidiary of Orgenesis Inc. (NASDAQ: ORGS). The transaction was signed on November 4, 2022, and closed on November 14, 2022.
About the Companies
Metalmark is a leading private equity firm that seeks to build long-term value through active and collaborative partnerships with business owners, founders, and executives. The firm focuses its investment activity in healthcare, agribusiness, and industrials. Metalmark manages funds with $3 billion in aggregate capital commitments.
Orgenesis created Morgenesis, the POCare Services subsidiary, to streamline all existing POCare Service business units into one unified entity, bringing together a full-service range of solutions for therapeutic developers for point of care treatments. The newly formalized service offering will provide solutions from initial process development, regulatory strategy and implementation, OMPULization (full cGMP process development, including closing/automating the process for point of care treatments), full cGMP processing and supply of therapeutic product to patients at the point of care, to clinical trial design and management.
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.